BACKGROUND: Lymph node metastases (LNMs) are rare in patients with soft tissue sarcoma (STS), and there is limited evidence to guide clinical management. We describe our experience with sentinel lymph node biopsy (SLNB) and lymphadenectomy in STS patients. METHODS: A single-center, retrospective review was performed for patients with STS treated with SLNB and/or lymphadenectomy from 1994 to 2018. Clinicopathologic characteristics, multimodality treatment, regional/distant recurrence-free survival (RFS), and overall survival (OS) were examined. RESULTS: Eighty-six patients underwent SLNB (n = 34) and/or lymphadenectomy (n = 60) for STS. The most frequent histologic subtypes were epithelioid, clear cell, and undifferentiated pleomorphic sarcoma. Eight of 34 (23.5%) patients had a positive SLNB with 5-year OS of 71.4% compared with 71.9% for those with a negative SLNB. Eight of the 26 SLN-negative patients (30.8%) eventually developed nodal recurrence (n = 2) and/or (n = 6) distant metastasis with an estimated 5-year OS of 50%. Of patients undergoing lymphadenectomy, estimated 5-year OS was 44.6% and median RFS was 12 months. Eight (13.3%) had distant disease at time of lymphadenectomy, 20 (33.3%) developed distant recurrence after lymphadenectomy, and 6 (10%) developed regional-only recurrence. Patients with regional-only recurrence after lymphadenectomy had an estimated 5-year OS of 66.7% compared with 29.1% for those who recurred distantly. CONCLUSIONS: Patients with positive SLNB had similar survival to those with negative SLNB. Lymphadenectomy for isolated nodal disease is associated with poor RFS but reasonable 5-year OS when recurrence is regional-only. In STS, regional disease appears clinically distinct from distant metastatic disease and has better outcomes.
BACKGROUND: Lymph node metastases (LNMs) are rare in patients with soft tissue sarcoma (STS), and there is limited evidence to guide clinical management. We describe our experience with sentinel lymph node biopsy (SLNB) and lymphadenectomy in STS patients. METHODS: A single-center, retrospective review was performed for patients with STS treated with SLNB and/or lymphadenectomy from 1994 to 2018. Clinicopathologic characteristics, multimodality treatment, regional/distant recurrence-free survival (RFS), and overall survival (OS) were examined. RESULTS: Eighty-six patients underwent SLNB (n = 34) and/or lymphadenectomy (n = 60) for STS. The most frequent histologic subtypes were epithelioid, clear cell, and undifferentiated pleomorphic sarcoma. Eight of 34 (23.5%) patients had a positive SLNB with 5-year OS of 71.4% compared with 71.9% for those with a negative SLNB. Eight of the 26 SLN-negative patients (30.8%) eventually developed nodal recurrence (n = 2) and/or (n = 6) distant metastasis with an estimated 5-year OS of 50%. Of patients undergoing lymphadenectomy, estimated 5-year OS was 44.6% and median RFS was 12 months. Eight (13.3%) had distant disease at time of lymphadenectomy, 20 (33.3%) developed distant recurrence after lymphadenectomy, and 6 (10%) developed regional-only recurrence. Patients with regional-only recurrence after lymphadenectomy had an estimated 5-year OS of 66.7% compared with 29.1% for those who recurred distantly. CONCLUSIONS: Patients with positive SLNB had similar survival to those with negative SLNB. Lymphadenectomy for isolated nodal disease is associated with poor RFS but reasonable 5-year OS when recurrence is regional-only. In STS, regional disease appears clinically distinct from distant metastatic disease and has better outcomes.
Authors: Emily Z Keung; Yi-Ju Chiang; Rachel K Voss; Janice N Cormier; Keila E Torres; Kelly K Hunt; Barry W Feig; Christina L Roland Journal: Eur J Surg Oncol Date: 2017-11-27 Impact factor: 4.424
Authors: Brett L Ecker; Madalyn G Peters; Matthew T McMillan; Andrew J Sinnamon; Paul J Zhang; Rachel R Kelz; Robert E Roses; Jeffrey A Drebin; Douglas L Fraker; Giorgos C Karakousis Journal: Ann Surg Oncol Date: 2016-10-26 Impact factor: 5.344
Authors: Georges Basile; Jean-Camille Mattei; Ibrahim Alshaygy; Anthony M Griffin; Charles N Catton; Peter W Chung; David B Shultz; Albiruni R A Razak; Elizabeth G Demicco; Peter C Ferguson; Jay S Wunder Journal: Cancer Date: 2020-09-10 Impact factor: 6.860
Authors: A Daigeler; C Kuhnen; R Moritz; I Stricker; O Goertz; D Tilkorn; L Steinstraesser; H U Steinau; M Lehnhardt Journal: Langenbecks Arch Surg Date: 2008-07-02 Impact factor: 3.445
Authors: Waddah B Al-Refaie; Robert H I Andtbacka; Joe Ensor; Peter W T Pisters; Tammy L Ellis; Anita Shrout; Kelly K Hunt; Janice N Cormier; Raphael E Pollock; Barry W Feig Journal: Cancer Date: 2008-04-15 Impact factor: 6.860
Authors: Joseph A Miccio; Vikram Jairam; Sarah Gao; Alexander Augustyn; Oluwadamilola T Oladeru; Benjamin E Onderdonk; Mudit Chowdhary; Dale Han; Sajid Khan; Gary Friedlaender; Dieter M Lindskog; Hari A Desphande; Heather Osborn; Kenneth B Roberts; Kirtesh R Patel Journal: Cureus Date: 2019-10-30